We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01515358
Recruitment Status : Completed
First Posted : January 24, 2012
Last Update Posted : May 31, 2012
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purposes of this study are to determine the safety and side effects of LY3000328, to determine how well the body will tolerate LY3000328, and to determine how long LY3000328 remains in the body.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Placebo Drug: LY3000328 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Subjects
Study Start Date : February 2012
Primary Completion Date : May 2012
Study Completion Date : May 2012

Arm Intervention/treatment
Placebo Comparator: Placebo
Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
Drug: Placebo
Administered orally
Experimental: LY3000328
Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
Drug: LY3000328
Administered orally



Primary Outcome Measures :
  1. Number of participants with one or more drug related adverse events (AEs) or any serious AEs [ Time Frame: Baseline to study completion (estimate 3 months) ]

Secondary Outcome Measures :
  1. Pharmacokinetics: Area under the concentration-time curve (AUC) of LY3000328 [ Time Frame: Pre-dose up to Day 6 post-dose ]
  2. Pharmacokinetics: Maximum concentration (Cmax) of LY3000328 [ Time Frame: Pre-dose up to Day 6 post-dose ]
  3. Change in Cathepsin S (CatS) activity [ Time Frame: Pre-dose, up to 48 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Are overtly healthy males or females, as determined by medical history and physical examination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01515358


Locations
Singapore
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Singapore, Singapore, 117597
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01515358     History of Changes
Other Study ID Numbers: 14340
I5U-MC-ANBB ( Other Identifier: Eli Lilly and Company )
First Posted: January 24, 2012    Key Record Dates
Last Update Posted: May 31, 2012
Last Verified: May 2012